Surgical adhesions, or the development of excessive scar tissue, are a near ubiquitous consequence following abdominopelvic or cardiac surgery. The National Center for Healthcare Statistics reports more than 32 million inpatient surgeries occur in the United States annually. Reports indicate surgical adhesion development occurs in 50-90% of gynecological, 70-90% of abdominal, and 60-90% of cardiac related surgeries and is the root cause of additional complications including significant pain, bowel obstruction, and infertility that lead to increased hospital. Direct and indirect costs attributed to the complications resulting from surgical adhesions are estimated to exceed $2 billion worldwide annually ($1.18 billion in the US). The market size for adhesion barrier films eclipses $500M globally with a CAGR of 7.2% through 2016. Our PXAD therapeutic film is composed of Parylene C, a USP Class VI Biocompatible polymer (ISO 10993 Certified) approved for permanent implantation in the body. The PXAD film remains as a permanent barrier after surgery to assure complete separation of adjacent tissues allowing for proper healing and can be integrated with therapeutics released in a site-specific manner. This product differs from traditional means of anti-adhesive barriers, which rely on the implementation of transient solutions or biodegradable films without the utilization of therapeutic agents achieving 50% reduction in adhesion scores. Compelling in vivo results validate the non-reactive PXAD film as a potent anti-adhesive barrier that achieves an 86% reduction in adhesion scores when compared to controls and a 91% reduction when combined with a potent anti-inflammatory drug targeting post-surgical inflammation.
|Effective start/end date||7/1/13 → 7/31/15|
- National Collegiate Inventors and Innovators Alliance, Inc. (Grant #10521-13)